1. Home
  2. KINS vs CGEN Comparison

KINS vs CGEN Comparison

Compare KINS & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KINS
  • CGEN
  • Stock Information
  • Founded
  • KINS 1886
  • CGEN 1993
  • Country
  • KINS United States
  • CGEN Israel
  • Employees
  • KINS N/A
  • CGEN N/A
  • Industry
  • KINS Property-Casualty Insurers
  • CGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • KINS Finance
  • CGEN Health Care
  • Exchange
  • KINS Nasdaq
  • CGEN Nasdaq
  • Market Cap
  • KINS 206.6M
  • CGEN 167.4M
  • IPO Year
  • KINS N/A
  • CGEN 2000
  • Fundamental
  • Price
  • KINS $15.80
  • CGEN $1.53
  • Analyst Decision
  • KINS
  • CGEN
  • Analyst Count
  • KINS 0
  • CGEN 0
  • Target Price
  • KINS N/A
  • CGEN N/A
  • AVG Volume (30 Days)
  • KINS 321.7K
  • CGEN 236.6K
  • Earning Date
  • KINS 08-07-2025
  • CGEN 08-06-2025
  • Dividend Yield
  • KINS N/A
  • CGEN N/A
  • EPS Growth
  • KINS 5417.04
  • CGEN N/A
  • EPS
  • KINS 1.60
  • CGEN N/A
  • Revenue
  • KINS $169,875,701.00
  • CGEN $27,589,000.00
  • Revenue This Year
  • KINS $41.35
  • CGEN N/A
  • Revenue Next Year
  • KINS $12.33
  • CGEN $105.77
  • P/E Ratio
  • KINS $9.90
  • CGEN N/A
  • Revenue Growth
  • KINS 18.52
  • CGEN N/A
  • 52 Week Low
  • KINS $6.02
  • CGEN $1.13
  • 52 Week High
  • KINS $22.40
  • CGEN $2.66
  • Technical
  • Relative Strength Index (RSI)
  • KINS 54.09
  • CGEN 41.35
  • Support Level
  • KINS $15.00
  • CGEN $1.49
  • Resistance Level
  • KINS $16.03
  • CGEN $1.64
  • Average True Range (ATR)
  • KINS 0.57
  • CGEN 0.08
  • MACD
  • KINS 0.13
  • CGEN -0.02
  • Stochastic Oscillator
  • KINS 80.37
  • CGEN 25.00

About KINS Kingstone Companies Inc.

Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company. It offers insurance policies to small and mid-sized businesses as well as to individuals.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: